What are the Effects of IBD Therapy During Pregnancy?

In pregnant women treated for inflammatory bowel diseases (IBD),  infliximab and adalimumab, but not certolizumab, cross the placenta and are detected in infants up to 6 months after birth, according to the March issue of Clinical Gastroenterology and Hepatology (CGH). However, they do not appear to cause birth defects, and women

Read more